Torsdag 9 April | 14:46:28 Europe / Stockholm
Svenska | English

BioStock

Prenumeration

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

Biosergen halts BSG005 development
2026-04-07 14:24:00

The challenging financing climate has forced Biosergen to pause its lead antifungal candidate, BSG005, as securing the required 60 million SEK is deemed unfeasible. This is a setback for a programme that recently received positive feedback from the FDA and showed clinical promise in treating life-threatening, resistant fungal infections. Strategic options now include an asset sale, merger, reverse takeover, or ultimately, a voluntary liquidation. BioStock contacted CEO Tine Kold Olesen for a comment.

Read the full article at biostock.se:

Biosergen halts BSG005 development

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Follow BioStock
Stay up to date with the latest news, upcoming events, recent videos, and podcasts! Subscribe to our newsletters at https://www.biostock.se/newsletter 
Follow BioStock on social media: LinkedIn and Facebook!  
 
About BioStock 
BioStock is the leading digital hub for the Nordic life science sector. Focusing on biotechnology, medical technology, diagnostics, and drug development, we provide daily news updates, in-depth analyses, exclusive interviews, and innovation-promoting networking events – all to keep you informed about industry developments.  
BioStock – Connecting Innovation & Capital. 

Källa MFN
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden